Choline kinase inhibition in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 74, Issue 7, 2015, Pages 1399-1407

  Guma, Monica ^a   Sanchez Lopez, E ^a   Lodi, A ^b   Garcia Carbonell, R ^a   Tiziani, S ^b   Karin, M ^a   Lacal, J C ^c   Firestein, G S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UAM)   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 [4,4' BIS[[4 (DIMETHYLAMINE)PYRIDINIUM 1 YL]METHYL]DIPHENYL]BUTANE DIBROMIDE; CHOLINE KINASE; INK 631; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHORYLCHOLINE; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; 1,4-(4-4'-BIS-((4-(DIMETHYLAMINE)PYRIDINIUM-1-YL) METHYL)DIPHENYL)BUTANE DIBROMIDE; BUTANE; CHOLINE; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN KINASE B; PYRIDINIUM DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; FIBROBLAST LIKE SYNOVIOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IN VITRO STUDY; LUNG FIBROBLAST; METABOLOMICS; MOUSE; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SKIN FIBROBLAST; SYNOVIOCYTE; SYNOVIUM; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; C57BL MOUSE; CELL MOTION; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; FIBROBLAST; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; ARTHRITIS, RHEUMATOID; BUTANES; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHOLINE; CHOLINE KINASE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FIBROBLASTS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINIUM COMPOUNDS; SYNOVIAL MEMBRANE;

EID: 84935003142     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205696     Document Type: Article

References (59)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
2. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010;233:233-55.
3. Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol 2013;9:24-33.
4. Lefevre S, Knedla A, Tennie C, et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nature medicine 2009;15:1414-20.
5. Eckhart AD, Beebe K, Milburn M. Metabolomics as a key integrator for "omic" advancement of personalized medicine and future therapies. Clin Transl Sci 2012;5:285-8.
6. Hugle T, Kovacs H, Heijnen IA, et al. Synovial fluid metabolomics in different forms of arthritis assessed by nuclear magnetic resonance spectroscopy. Clin Exp Rheumatol 2012;30:240-5.
7. Lauridsen MB, Bliddal H, Christensen R, et al. 1H NMR spectroscopy-based interventional metabolic phenotyping: a cohort study of rheumatoid arthritis patients. J Proteome Res 2010;9:4545-53.
8. Madsen RK, Lundstedt T, Gabrielsson J, et al. Diagnostic properties of metabolic perturbations in rheumatoid arthritis. Arthritis Res Ther 2011;13:R19.
9. Priori R, Scrivo R, Brandt J, et al. Metabolomics in rheumatic diseases: the potential of an emerging methodology for improved patient diagnosis, prognosis, and treatment efficacy. Autoimmun Rev 2013;12:1022-30.
10. Young SP, Kapoor SR, Viant MR, et al. The impact of inflammation on metabolomic profiles in patients with arthritis. Arthritis Rheum 2013;65:2015-23.
11. Casado-Vela J, Cebrian A, Gomez del Pulgar MT, et al. Approaches for the study of cancer: towards the integration of genomics, proteomics and metabolomics. Clin Transl Oncol 2011;13:617-28.
12. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, et al. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7:11-20.
13. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008;134:703-07.
14. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer 2011;11:835-48.
15. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004;64:4270-6.
16. Iorio E, Mezzanzanica D, Alberti P, et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res 2005;65:9369-76.
17. Romanska HM, Tiziani S, Howe RC, et al. Nuclear Magnetic Resonance Detects Phosphoinositide 3-Kinase/Akt-Independent Traits Common to Pluripotent Murine Embryonic Stem Cells and Their Malignant Counterparts. Neoplasia 2009;11:1301.
18. Lacal JC. Choline kinase: a novel target for antitumor drugs. IDrugs 2001;4:419-26.
19. Glunde K, Jiang L, Moestue SA, et al. MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer. NMR Biomed 2011;24:673-90.
20. Rodriguez-Gonzalez A, Ramirez de Molina A, Fernandez F, et al. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene 2003;22:8803-12.
21. Ramirez de Molina A, Gutierrez R, Ramos MA, et al. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 2002;21:4317-22.
22. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002;296:580-3.
23. Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, et al. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol 2007;8:889-97.
24. Li M, Peng Z, Liu Q, et al. Value of 11C-choline PET/CT for lung cancer diagnosis and the relation between choline metabolism and proliferation of cancer cells. Oncol Rep 2013;29:205-11.
25. Zimmerman T, Moneriz C, Diez A, et al. Antiplasmodial Activity and Mechanism of Action of RSM-932A, a Promising Synergistic Inhibitor of Plasmodium falciparum Choline Kinase. Antimicrob Agents Chemother 2013;57:5878-88.
26. Cuadrado A, Carnero A, Dolfi F, et al. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene 1993;8:2959-68.
27. Jimenez B, del Peso L, Montaner S, et al. Generation of phosphorylcholine as an essential event in the activation of Raf-1 and MAP-kinases in growth factors-induced mitogenic stimulation. J Cell Biochem 1995;57:141-9.
28. Li Z, Wu G, van der Veen JN, et al. Phosphatidylcholine metabolism and choline kinase in human osteoblasts. Biochim Biophys Acta 2014;1841:859-67.
29. Mori N, Gadiya M, Wildes F, et al. Characterization of choline kinase in human endothelial cells. NMR Biomed 2013;26:1501-7.
30. Yalcin A, Clem B, Makoni S, et al. Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling. Oncogene 2010;29:139-49.
31. Chua BT, Gallego-Ortega D, Ramirez de Molina A, et al. Regulation of Akt(ser473) phosphorylation by choline kinase in breast carcinoma cells. Mol Cancer 2009;8:131.
32. Glunde K, Bhujwalla ZM. Metabolic tumor imaging using magnetic resonance spectroscopy. Semin Oncol 2011;38:26-41.
33. Hernandez-Alcoceba R, Fernandez F, Lacal JC. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res 1999;59:3112-18.
34. Bartok B, Boyle DL, Liu Y, et al. PI3 kinase delta is a key regulator of synoviocyte function in rheumatoid arthritis. Am J Pathol 2012;180:1906-16.
35. Kyburz D, Corr M. The KRN mouse model of inflammatory arthritis. Springer Semin Immunopathol 2003;25:79-90.
36. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60:1895-905.
37. Sweeney SE, Firestein GS. Primer: signal transduction in rheumatic disease - a clinician's guide. Nat Clin Pract Rheumatol 2007;3:651-60.
38. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:3309-18.
39. Pearce EL, Poffenberger MC, Chang CH, et al. Fueling immunity: insights into metabolism and lymphocyte function. Science 2013;342:1242454.
40. Wang R, Green DR. Metabolic checkpoints in activated T cells. Nat Immunol 2012;13:907-15.
41. McDonald G, Deepak S, Miguel L, et al. Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. J Clin Invest 2014;124:712-24.
42. Gaber T, Dziurla R, Tripmacher R, et al. Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do! Ann Rheum Dis 2005;64:971-80.
43. Ramirez de Molina A, Gallego-Ortega D, Sarmentero-Estrada J, et al. Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy. Int J Biochem Cell Biol 2008;40:1753-63.
44. Lee DM, Kiener HP, Agarwal SK, et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science 2007;315:1006-10.
45. Gallego-Ortega D, Gomez del Pulgar T, Valdes-Mora F, et al. Involvement of human choline kinase alpha and beta in carcinogenesis: a different role in lipid metabolism and biological functions. Adv Enzyme Regul 2011;51:183-94.
46. Gallego-Ortega D, Ramirez de Molina A, Ramos MA, et al. Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment. PLoS ONE 2009;4:e7819.
47. Kosinska MK, Liebisch G, Lochnit G, et al. A lipidomic study of phospholipid classes and species in human synovial fluid. Arthritis Rheum 2013;65:2323-33.
48. Schwarz IM, Hills BA. Synovial surfactant: lamellar bodies in type B synoviocytes and proteolipid in synovial fluid and the articular lining. Br J Rheumatol 1996;35:821-7.
49. Ramirez de Molina A, Banez-Coronel M, Gutierrez R, et al. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res 2004;64:6732-9.
50. Alvaro-Gracia JM, Zvaifler NJ, Brown CB, et al. Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha. J Immunol 1991;146:3365-71.
51. Schipper RG, van den Heuvel LP, Verhofstad AA, et al. Polyamines and DNA methylation in childhood leukaemia. Biochem Soc Trans 2007;35:331-5.
52. Alvaro-Gracia JM, Zvaifler NJ, Firestein GS. Cytokines in chronic inflammatory arthritis. V. Mutual antagonism between interferon-gamma and tumor necrosis factor-alpha on HLA-DR expression, proliferation, collagenase production, and granulocyte macrophage colony-stimulating factor production by rheumatoid arthritis synoviocytes. J Clin Invest 1990;86:1790-8.
53. Tiziani S, Lodi A, Khanim FL, et al. Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines. PLoS One 2009;4:e4251.
54. Wu H, Southam AD, Hines A, et al. High-throughput tissue extraction protocol for NMR- and MS-based metabolomics. Analytical Biochemistry 2008;372:204-12.
55. Ludwig C, Gunther UL. MetaboLab - advanced NMR data processing and analysis for metabolomics. BMC Bioinformatics 2011;12:366.
56. Dieterle F, Ross A, Schlotterbeck G, et al. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal Chem 2006;78:4281-90.
57. Psychogios N, Hau DD, Peng J, et al. The human serum metabolome. PLoS ONE 2011;6:e16957.
58. Quehenberger O, Armando AM, Brown AH, et al. Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res 2010;51:3299-305.
59. Wishart DS, Tzur D, Knox C, et al. HMDB: the Human Metabolome Database. Nucleic Acids Res 2007;35:D521-6.